Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 13/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TACR2 | P21452 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367561 | 0.85 | SLC6A9 (0.41) | TACR3ADORA2AADORA1SLC2A1SLC6A9 | |
| SCHEMBL4357027 | 0.83 | TACR3 (0.46) | TACR3ADORA2AADORA1SLC2A1CYP1A2 | |
| SCHEMBL4361680 | 0.82 | TACR3 (0.45) | TACR3ADORA2AADORA1SLC2A1CYP1A2 | |
| SCHEMBL4358870 | 0.80 | TACR3 (0.43) | TACR3ADORA2AADORA1SLC2A1TACR2 | |
| SCHEMBL1349793 | 0.78 | SLC6A9 (0.52) | SLC6A9 | |
| SCHEMBL3241393 | 0.78 | SLC6A9 (0.49) | SLC6A9 | |
| SCHEMBL4363718 | 0.78 | TACR3 (0.43) | TACR3ADORA2AADORA1SLC2A1TACR2 | |
| SCHEMBL4355252 | 0.77 | TACR3 (0.53) | TACR3ADORA2AADORA1SLC2A1CYP1A2 | |
| SCHEMBL12132751 | 0.76 | CTSL (0.47) | — | |
| SCHEMBL3244222 | 0.76 | SLC6A9 (0.65) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | PNMT, SLC18A2, COMT | TACR3 2005/4885ADORA2A 717/4885ADORA1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.